Patents Examined by Martha T. Lubet
-
Patent number: 6207389Abstract: Methods and compositions are provided for preventing the development of a T cell mediated autoimmune disease such as Type I diabetes, in which susceptible subjects have T cells sensitized to a disease-related antigen. Subjects are treated by administration of the antigen or fragments thereof to prevent the expansion of the population of sensitized T cells. Alternatively, subjects are treated by administration of immunogenic compositions comprising a mimicry antigen or fragments thereof.Type: GrantFiled: June 7, 1995Date of Patent: March 27, 2001Assignee: HRC Research and Development Limited PartnershipInventor: Hans Michael Dosch
-
Patent number: 6130087Abstract: The present invention provides methods for generating antigen-reactive cytotoxic T cells in vitro comprising culturing immune cells and antigenic cells that have at least one MHC allele in common (and preferably, are syngeneic), in which the antigenic cells have been treated according to the methods of the invention. The antigenic cells are treated by subjecting them to osmotic shock followed by irradiation. As a result, a subset of T cells are activated and mature into antigen-reactive cytotoxic T cells. The effectiveness of the procedure may be enhanced by repeated restimulations and/or the addition of heat shock protein-peptide complexes. Methods and compositions are also disclosed for the treatment and prevention in a subject of cancer or infectious disease comprising administering to the subject matched cytotoxic T cells that are generated in vitro by the present methods.Type: GrantFiled: October 7, 1996Date of Patent: October 10, 2000Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Robert Binder, Nathalie E. Blachere
-
Patent number: 6020477Abstract: An isolated DNA molecule consisting of SEQ I.D. No: 22 encoding a polypeptide having a protease activity and capable of inducing a apoptosis and the method of producing a polypeptide consisting of the said sequence.Type: GrantFiled: April 30, 1997Date of Patent: February 1, 2000Assignee: Hoechst Marion RousselInventors: Anita Diu, Chi Faucheu, Thierry Hercend, Jean Louis Lalanne, David J Livingston, Michael Su
-
Patent number: 5928938Abstract: The invention involves the identification of peptides which complex with HLA-Cw.sup.* 16 molecules, and which may then provoke lysis of the cells to which they bind, by cytolytic T cells. Diagnostic and therapeutic uses are described.Type: GrantFiled: December 19, 1997Date of Patent: July 27, 1999Assignee: Ludwig Institute for Cancer ResearchInventors: Pierre van der Bruggen, Etienne DePlaen, Thierry Boon-Falleur
-
Patent number: 5869055Abstract: The invention relates to anti-inflammatory polypeptides comprising soluble CD14 related polypeptides having amino acids at position 7-10 that are different from the native sequence or having amino acids 1-14 deleted.Type: GrantFiled: June 7, 1995Date of Patent: February 9, 1999Assignee: Amgen, Inc.Inventors: Shao-Chieh Juan, Henri S. Lichenstein, Samuel D. Wright
-
Patent number: 5859223Abstract: Soluble polypeptides are provided that comprise no more than three short consensus repeats (SCR) of Complement Receptor 1, and contain SCR3. DNA molecules encoding such soluble polypeptides, as well as methods, vectors and host cells, also are provided.Type: GrantFiled: December 19, 1996Date of Patent: January 12, 1999Assignee: AdProTech PlcInventors: Danuta Ewa Irena Mossakowska, Ian Dodd, Anne Mary Freeman, Richard Anthony Godwin Smith
-
Patent number: 5849879Abstract: A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.Type: GrantFiled: May 14, 1996Date of Patent: December 15, 1998Assignee: The Regents of the University of CaliforniaInventors: Thai D. Nguyen, Jon R. Polansky, Weidong Huang
-
Patent number: 5821125Abstract: The present invention provides novel PKA-binding polypeptides, nucleic acids that encode the polypeptides and antibodies specifically immunoreactive with the polypeptides.Type: GrantFiled: May 29, 1997Date of Patent: October 13, 1998Assignee: ICOS CorporationInventors: Robert Owen Lockerbie, W. Michael Gallatin
-
Patent number: 5780597Abstract: The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.Type: GrantFiled: June 2, 1995Date of Patent: July 14, 1998Assignee: Hoffmann-La Roche Inc.Inventors: Maurice Kent Gately, Ulrich Andreas Gubler, Jeffrey David Hulmes, Frank John Podlaski, Alvin Seth Stern, Richard Anthony Chizzonite, Yu-Ching Eugene Pan
-
Patent number: 5731420Abstract: The present invention provides an isolated nucleic acid molecule encoding both a soluble and membrane-bound human .beta.-1,6-N-acetylglucosaminyltransferase, the I-branching enzyme (IGnT). The invention also provides vectors containing the isolated nucleic acid molecule encoding human IGnT as well as recombinant host cells transformed with the vectors. The invention further provides a method of preparing a membrane-bound form of human IGnT and methods of preparing and purifying soluble human IGnT and active fragments of either form. Also provided are antisense oligonucleotides complementary to a nucleic acid molecule encoding a human IGnT or an active fragment thereof, antibodies directed to the human IGnT, pharmaceutical compositions related to the human IGnT and transgenic nonhuman mammals expressing DNA encoding normal or mutant human IGnT. Also provided are methods for regulating the expression of human IGnT and methods for modifying a biological function mediated by the regulatory activity of human IGnT.Type: GrantFiled: June 7, 1995Date of Patent: March 24, 1998Assignee: La Jolla Cancer Research FoundationInventors: Minoru Fukuda, Marti F. A. Bierhuizen
-
Patent number: 5728560Abstract: The present invention is directed to methods of treating CD4+ T cell lymphopenia in HIV-infected patients. The methods include administering an effective mount of adenosine deaminase or related enzymatic material to a patient in need thereof. In preferred aspects of the invention, the method is employed in conjunction with HIV-infected patients having CD4+ T cell levels of less than about 200/.mu.l. Effective amounts of the enzyme range from about 5 to about 50 IU/kg/week. In one particularly preferred aspect of the invention, the adenosine deaminase is conjugated to one or more strands of polyethylene glycol to prolonged activity in vivo.Type: GrantFiled: June 14, 1996Date of Patent: March 17, 1998Assignee: Enzon, Inc.Inventors: Robert G. L. Shorr, Mike A. Clark, David H. Goddard
-
Patent number: 5684134Abstract: The present invention provides a novel .beta.1.fwdarw.6 N-acetylglucosaminyltransferase, which forms core 2 oligosaccharide structures in O-glycans, and a novel acceptor molecule, leukosialin, CD43, for core 2 .beta.1.fwdarw.6 N-acetylglucosaminyltransferase activity. The amino acid sequences and nucleic acid sequences encoding these molecules, as well as active fragments thereof, also are disclosed. A method for isolating nucleic acid sequences encoding proteins having enzymatic activity is disclosed, using CHO cells that support replication of plasmid vectors having a polyoma virus origin of replication. A method to obtain a suitable cell line that expresses an acceptor molecule also is disclosed.Type: GrantFiled: June 7, 1995Date of Patent: November 4, 1997Assignee: La Jolla Cancer Research CenterInventors: Minoru Fukuda, Marti F. A. Bierhuizen
-
Patent number: 5677430Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.Type: GrantFiled: December 12, 1995Date of Patent: October 14, 1997Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss